P-Glycoprotein - Antagonists & inhibitors
Research News and Information

Monday, November 23, 2009

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.

13 Nov 2009 Accumulating evidence suggests that tumors are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. Recently, there have been efforts to explain drug resistance of ... Read more...

Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier.

6 Oct 2009 With the aim to develop a positron emission tomography (PET) tracer to assess the distribution of P-glycoprotein (P-gp) at the blood-brain barrier (BBB) in vivo, the potent third-generation P-gp inhibitor elacridar (1) was labeled with (11)C by ... Read more...

Novel pepper extract for enhanced P-glycoprotein inhibition.

30 Aug 2009 OBJECTIVES: Piperine is one of the most promising bioenhancers to date. Methods used for its extraction suffer from drawbacks such as use of organic solvents, poor extraction efficiency, tedious and expensive methodology. These methods are not ... Read more...

Latest indexed articles for 'P-Glycoprotein - Antagonists & inhibitors'

These are the very latest articles for this heading:

• CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. 13 Nov 2009
• Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. 6 Oct 2009
• Novel pepper extract for enhanced P-glycoprotein inhibition. 30 Aug 2009
• Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux. 30 Aug 2009
• Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. 12 Aug 2009
• Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships. 11 Aug 2009
• A novel, promoter-based, target-specific assay identifies 2-deoxy-D-glucose as an inhibitor of globotriaosylceramide biosynthesis. 8 Aug 2009
• Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. 30 Jul 2009
• Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. 30 Jul 2009
• Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. 29 Jul 2009
• Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123. 21 Jul 2009
• Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. 15 Jul 2009
• Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Jul 2009
• Functionalized silicon quantum dots tailored for targeted siRNA delivery. 30 Jun 2009
• Transport characteristics of candesartan in human intestinal Caco-2 cell line. 29 Jun 2009
• Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. 29 Jun 2009
• Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier. 29 Jun 2009
• P-glycoprotein interfering agents potentiate ivermectin susceptibility in ivermectin sensitive and resistant isolates of Teladorsagia circumcincta and Haemonchus contortus. 22 Jun 2009
• Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. 7 Jun 2009
• P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. 31 May 2009

See a longer list of these articles.

Technical information about 'P-Glycoprotein'

Definition: A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).

Registry Number: 0

Descriptor UI: D020168

Alternative terms: P-Glycoprotein; P Glycoprotein; PGY-1 Protein; PGY 1 Protein; Multidrug Resistance Protein 1; ATP-Binding Cassette, Sub-Family B, Member 1; P-gp; MDR1 Protein;

Related Mesh Headings: Drug Resistance, Multiple;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.157.530.100.652.500; D12.776.157.530.450.074.500.500.750; D12.776.395.550.020.610.610; D12.776.543.550.192.610.610; D12.776.543.585.100.610.500; D12.776.543.585.450.074.500.500.750;

History Note: 99; use P-GLYCOPROTEIN 1995-98

Technical Notes: P-GLYCOPROTEINS is also available